Rein Therapeutics Inc (RNTX) Quarterly Institutional 13F Update (Q2 2026)

RNTX ranks #5705 out of 37696 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

RNTX is a top-conviction position for BIOS Capital Management, LP — at 7.4% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in RNTX belongs to Voss Capital, LP, but the position matters far more to BIOS Capital Management, LP, who has 7.4% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

Gleason Group, Inc. has trimmed its RNTX position for two straight quarters, cutting it by $11.1K while still holding $18.0K.

RNTX is up 7.2% today, and institutions have been net buyers of $30.6M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

RNTX reported a net loss of $49.8M over the trailing twelve months.

• Not yet profitable — net loss of $49.8M over the trailing twelve months
• Net income improved year over year, from -$59.2M to -$49.8M
• Operating cash flow was negative, using $19.4M in cash
• Current ratio of 0.70x — below the conventional 1.5x liquidity buffer
• Liabilities run 0.30x equity — within a conventional range